Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

118.37 -0.65 (-0.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
Xilio Revenue Jumps 246 Percent in Q2
Via The Motley Fool
Topics Intellectual Property
Gilead Sciences’s Q2 Earnings Call: Our Top 5 Analyst Questions
Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and the launch of Yeztugo, its twice-yearly injectable for HIV prevention.... 
Via StockStory
Topics Earnings
Q2 Rundown: Gilead Sciences (NASDAQ:GILD) Vs Other Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers. 
Via StockStory
Topics Artificial Intelligence
Gilead Stock Showered With Upgrades, Price Target Hikes After Upbeat Q2, Guidance Lift: Retail’s Turned Exuberant
Via Stocktwits
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Gilead Sciences's Earnings Outlook
 
Via Benzinga
Is Gilead Sciences Gaining or Losing Market Support?
 
Via Benzinga
GILD Q2 Deep Dive: HIV Franchise Drives Growth, New Launches and Pipeline in Focus
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 1.8% year on year to $7.08 billion. On the other hand, the company’s... 
Via StockStory
Kymera Revenue Drops 55 Percent in Q2
Via The Motley Fool
Topics Intellectual Property
Market Monitor News August 11 BMO - Nasdaq Breaks Records, But The Trade Desk Hits a Wall
Markets ended the week in high spirits, but not everyone joined the party. 
Via Chartmill
Gilead Sciences Shares Soar; Analysts Lift Targets On HIV Strength And Yeztugo Outlook
Upbeat guidance boosts confidence despite competitive pressures. 
Via Talk Markets
Wall Street's Resilient Rally: What's Driving the Positive Momentum
Wall Street has experienced a broadly positive day, marked by a resilient rally that has added over $1 trillion in market value. This surge in investor confidence is primarily driven by a confluence of... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
Earnings Season Boosts Confidence: Gilead and Expedia Lead Strong Corporate Results
The second quarter 2025 earnings season has largely concluded, delivering a powerful shot of optimism to the financial markets. Against a backdrop of persistent economic uncertainties and geopolitical... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Top S&P500 movers in Friday's session
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
Tech Stocks Eye Record Highs As Magnificent Seven Top $19.5 Trillion: What's Moving Markets Friday?
Tech stocks staged a full rebound from last Friday's sell-off, with the Nasdaq 100 surging to 23,600 — just shy of the 23,700 all-time high set in late July, as the week’s strong sector earnings and... 
Via Benzinga
Earnings Season Highlights: Gilead Sciences and Expedia Group Post Strong Results
The second quarter of 2025 has largely concluded as a period of unexpected strength for U.S. corporations, with a significant number of companies not only meeting but exceeding analyst expectations.... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
Friday's session: top gainers and losers in the S&P500 index
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Friday. 
Via Chartmill
Why Is Gilead Sciences (GILD) Stock Rocketing Higher Today
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.7% in the morning session after the company reported second-quarter 2025 results that topped Wall Street's expectations and... 
Via StockStory
Topics Earnings
Gilead Lifts Annual Outlook As Yeztugo Launch Nears
Gilead raised its 2025 earnings and sales outlook after posting better-than-expected Q2 results, led by strong HIV and oncology drug sales. 
Via Benzinga
SoundHound AI, Ouster, Globalstar, Doximity, JFrog And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Topics Artificial Intelligence
Discover the top S&P500 movers in Friday's pre-market session.
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. 
Via Chartmill
Gilead Sciences (GILD) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Gilead Sciences (NASDAQ:GILD) Beats Q2 Sales Targets
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 1.8% year on year to $7.08 billion. On the other hand, the... 
Via StockStory
Will Gilead's Beat-And-Raise Help It Leapfrog Its 50-Day Line Ceiling?
Gilead Sciences boosted its full-year outlook after beating expectations. Gilead stock is hitting a 50-day line ceiling. 
Via Investor's Business Daily
Gilead Sciences Announces Second Quarter 2025 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
How To Earn $500 A Month From Gilead Sciences Stock Ahead Of Q2 Earnings
 
Via Benzinga
Apple Jumps, Eli Lilly Crashes On Worst Day In 25 Years: What's Moving Markets Thursday?
U.S. equities slipped midday Thursday as corporate earnings and fresh tariff announcements from President Donald Trump drove divergent moves in heavyweight names. 
Via Benzinga
Topics Government World Trade
Arcus (RCUS) Q2 Revenue Jumps 310%
Via The Motley Fool
Upcoming Earnings Calls This Week: August 4th - August 10th, 2025
This week, from August 4th to August 10th, 2025, marks a busy period in the second-quarter earnings season, with hundreds of companies across various sectors scheduled to report their financial... 
Via MarketMinute
Topics Artificial Intelligence Economy
Gilead Sciences Inc (NASDAQ:GILD) Meets Caviar Cruise Quality Investing Criteria
The Caviar Cruise strategy identifies high-quality stocks like Gilead Sciences (GILD) for long-term investment, focusing on strong growth, ROIC, low debt, and solid cash flow. GILD excels in... 
Via Chartmill
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.